Trials / Conditions / Pathological Complete Response

Pathological Complete Response

16 registered clinical trials studyying Pathological Complete Response — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Tissue- and Serum-Derived Exosomal microRNAs as Predictors of Neoadjuvant Chemotherapy Response in Breast Canc NCT07500129	Atlas University	—
Active Not Recruiting	Predicting Pathological Complete Response in Rectal Cancer Using Machine Learning NCT07509632	Peking University People's Hospital	—
Recruiting	Neoadjuvant Immunochemotherapy and Chemoradiotherapy Followed by Surgery for Advanced Esophageal Squamous Cell NCT06764355	National Taiwan University Hospital	Phase 2
Recruiting	Deep Learning Model Predicts Pathological Complete Response of Esophageal Squamous Cell Carcinoma Following Ne NCT07088354	Tongji Hospital	—
Unknown	Deep Learning Model Predicts Pathological Complete Response of Lung Cancer Following Neoadjuvant Immunochemoth NCT06285058	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	—
Recruiting	Omission of ALND in Breast Cancer Patients With Axillary pCR NCT05939830	The First Affiliated Hospital with Nanjing Medical University	N/A
Suspended	Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormone Receptor Postive (HR+), HER2- Breast Cancer NCT05503108	Leiden University Medical Center	Phase 3
Active Not Recruiting	Clinical Study on the Safety and Relationship of Sintilimab Combined With Chemotherapy in Neoadjuvant Treatmen NCT07127497	The First Affiliated Hospital of Anhui Medical University	Phase 2
Unknown	Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therap NCT04848454	Peking University First Hospital	Phase 2
Unknown	THeragnostic Utilities for Neoplastic DisEases of the Rectum by MRI Guided Radiotherapy NCT04815694	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	N/A
Completed	Predicting Pathological Complete Response in Esophageal Squamous Cell Carcinoma Using a Multimodal Model Integ NCT07181850	Nanjing Medical University	—
Unknown	Effect of Concurrent Capecitabine-based Long-term Radiotherapy Followed by XELOX Plus TME in Patients With Hig NCT03038256	Peking University People's Hospital	Phase 2
Unknown	Pathological Complete Response Rate in Locally Advanced Breast Cancer With FEC, EC-T, or TC as Neoadjuvant Che NCT03349177	Zhiyong Yu	Phase 2 / Phase 3
Completed	RISAS Procedure in Node Positive Breast Cancer Following NAC NCT02800317	Erasmus Medical Center	N/A
Completed	DIetary REstriction as an Adjunct to Neoadjuvant ChemoTherapy for HER2 Negative Breast Cancer NCT02126449	Leiden University Medical Center	Phase 2 / Phase 3
Completed	Long-term Survival Outcomes According to the Pathologic Response After Neoadjuvant Treatment in PDAC and the F NCT06630481	Seoul National University Hospital	—